ARTICLE | Product Development
BIO leaders urge industry to hew to norms for COVID-19 candidates
Biotech KOLs warn public trust is on the line
September 3, 2020 10:03 AM UTC
Against a backdrop of questions about FDA’s independence, eight past and present members of BIO’s leadership team have written an open letter calling on industry to hold fast to its principles.
The letter, released Thursday, was signed by BIO President and CEO Michelle McMurry-Heath, Chair Jeremy Levin, Vice Chair Paul Hastings, Emerging Companies Chair Ted Love as well as past chairs Ron Cohen, Rachel King, John Maraganore and Richard Pops...